218 related articles for article (PubMed ID: 32017292)
1. Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Tang H; Yang K; Li X; Song Y; Han J
Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):161-172. PubMed ID: 32017292
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
[TBL] [Abstract][Full Text] [Related]
3. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.
Liu Y; Tian Q; Yang J; Wang H; Hong T
Diabetes Metab Res Rev; 2018 Nov; 34(8):e3061. PubMed ID: 30109766
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
[TBL] [Abstract][Full Text] [Related]
5. Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials.
Shi FH; Li H; Yue J; Jiang YH; Gu ZC; Ma J; Lin HW
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841351
[TBL] [Abstract][Full Text] [Related]
6. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Seidu S; Kunutsor SK; Topsever P; Khunti K
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
[TBL] [Abstract][Full Text] [Related]
7. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
Dicembrini I; Montereggi C; Nreu B; Mannucci E; Monami M
Diabetes Res Clin Pract; 2020 Jan; 159():107981. PubMed ID: 31870827
[TBL] [Abstract][Full Text] [Related]
8. Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials.
Cheng L; Li YY; Hu W; Bai F; Hao HR; Yu WN; Mao XM
Diabetes Metab; 2019 Oct; 45(5):436-445. PubMed ID: 30738154
[TBL] [Abstract][Full Text] [Related]
9. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
10. Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Li D; Wu T; Wang T; Wei H; Wang A; Tang H; Song Y
Pharmacoepidemiol Drug Saf; 2020 May; 29(5):582-590. PubMed ID: 32124527
[TBL] [Abstract][Full Text] [Related]
11. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
13. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.
Tsai WH; Chuang SM; Liu SC; Lee CC; Chien MN; Leung CH; Liu SJ; Shih HM
Sci Rep; 2021 Jul; 11(1):15364. PubMed ID: 34321571
[TBL] [Abstract][Full Text] [Related]
14. Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis.
Wang A; Yang K; Wang T; Zhang N; Tang H; Feng X
Diabetes Metab Res Rev; 2020 Jan; 36(1):e3174. PubMed ID: 31050384
[TBL] [Abstract][Full Text] [Related]
15. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
Sci Rep; 2019 Sep; 9(1):13009. PubMed ID: 31506585
[TBL] [Abstract][Full Text] [Related]
16. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
Wang H; Yang J; Chen X; Qiu F; Li J
Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials.
Azharuddin M; Adil M; Ghosh P; Sharma M
Diabetes Res Clin Pract; 2018 Dec; 146():180-190. PubMed ID: 30389620
[TBL] [Abstract][Full Text] [Related]
18. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z; Li G
Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
[TBL] [Abstract][Full Text] [Related]
19. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Mori Y; Duru OK; Tuttle KR; Fukuma S; Taura D; Harada N; Inagaki N; Inoue K
J Clin Endocrinol Metab; 2022 Dec; 108(1):221-231. PubMed ID: 36217306
[TBL] [Abstract][Full Text] [Related]
20. The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis.
Bai Y; Jin J; Zhou W; Zhang S; Xu J
Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1365-1374. PubMed ID: 33812735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
